Disclaimer: I am not a medical doctor and this is not medical advice. My goal is to empower you with information. I will not take a position on whether you should or should not get vaccinated. Please make this decision yourself, consulting sources you trust, including a caring health care professional.
In my last post, I laid out the argument that all-cause mortality is the most important metric to look at for evaluating the risk and reward of COVID vaccines. We saw that the American observational data appears to be hidden and obfuscated by the CDC. The English observational data, by contrast, suggests that among young people the vaccinated might be dying at twice the rate as the unvaccinated, but that this data is hopelessly confounded by grouping everyone between the ages of 10 and 59 together. We also saw that, among those over 60, the vaccinated appeared to have an initial mortality benefit during the COVID wave at the beginning of this year, but their benefit spent the rest of the year nosediving. It has now almost disappeared and may or may not be headed for a net mortality increase in the months to come.
The observational data is all confounded by variations in health status, health-seeking and health care-seeking behavior, diet, lifestyle, and lack of control for the distance of time between vaccination and death.
When dealing with such confounders, we must turn to the clinical trials. Since they are large and randomized, they tend to randomly distribute all known and unknown confounders between groups. So, today, we turn to the six-month results of the Pfizer trial. Was all-cause mortality impacted? As we will see, the differences are not statistically significant, but there is cause for concern that the vaccine could be increasing the risk of lethal heart disease.
The Design of the Trial
It is somewhat misleading to call this the “six-month” results of the Pfizer trial. After a two-month followup, which was really a 6-week followup from being “fully vaccinated” (a median of 2 months following the second dose, which is six weeks after the two-week waiting period to be considered “fully vaccinated”), the emergency use authorization (EUA) was given. The cutoff for the “two-month” data used to grant the EUA was October 9, 2020, while the EUA was given on December 11, allowing an additional two months of followup.
Once the EUA was given, the trial participants were given the option to learn which group they were in. If they were in the placebo group, they were given the option to be vaccinated.
Continue reading on Source: Did the Pfizer Trial Show the Vaccine Increases Heart Disease Deaths?
Originally discovered on LewRockwell.com